Pinokalant  (Synonyms: LOE-908)

Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity^[1].

Pinokalant significantly reduces cortical infarct volume from 33.8 mm³ to 24.5 mm^3[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

712.83

C₄₁H₄₈N₂O₉

149759-26-2

Solid

Off-white to light yellow

O=C(C(C1=NCCC2=C1C=C(C(OC)=C2)OC)C3=CC=CC=C3)N(CCC4=CC=C(C(OC)=C4OC)OC)CCC5=CC=C(C(OC)=C5OC)OC

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Christensen T, et al. The broad-spectrum cation channel blocker pinokalant (LOE 908 MS) reduces brain infarct volume in rats: a temperature-controlled histological study. Basic Clin Pharmacol Toxicol. 2005 Apr;96(4):316-24.  [Content Brief]

  [2]. Simard JM, et al. Non-selective cation channels, transient receptor potential channels and ischemic stroke. Biochim Biophys Acta. 2007 Aug;1772(8):947-57.  [Content Brief]

  [3]. Serdar Durdagi, et al. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study. 2020.